Skip to main content Skip to navigation

[University home]

School of Medicine

Professor Tony Heagerty MBBS, MD, FRCP, FAHA, FMedSci

Photograph of Tony Heagerty

Professor of Medicine and Head of the Cardiovascular Research Group

Cardiovascular Research Group
Core Technology Facility (3rd floor)
46 Grafton Street
Manchester
M13 9NT

 

Role

Professor of Medicine and Honorary Consultant Physician, University of Manchester and Central Manchester Foundation Trust and Head of the Cardiovascular Research Group in the School of Medicine.

 

Memberships of Committees and Professional Bodies

  • Academy of Medical Sciences
  • American Heart Association (Fellow)
  • Association of Physicians of Great Britain and Ireland
  • Medical Research Society
  • European Society of Cardiology
  • British Cardiovascular Society
  • International Fellow of the High Blood Pressure Council of the American Heart Association
  • International Society of Hypertension (President)
  • European Society of Hypertension (Past President)
  • The Venezuelan Society of Hypertension 2009 (Honorary Member)
  • British Hypertension Society (Vice-President)
  • London Blood Pressure Club
  • Manchester Medical Society
  • 1942 Club
  • British Atherosclerosis Society
  • Association of Clinical Professors of Medicine
  • National Academy of Medical Sciences (Founder Member)
  • The Athenaeum, London
  • International Society of Diabetes and Vascular Disease (ISDVD)
  • Physiological Society

Research

Our current research is to look prinicipally at the effects of fats surrounding small arteries and its influence on vascular tone.  There is an increasing body of evidence to suggest that the release of substances from fat cells can influence both vascular contraction and relaxation.  In pathological states such as obesity and diabetes there appears to be a loss of some of the healthy factors which leads to an increase in arterial contraction and higher blood pressures. Our group was the first to report that in human arteries the bioavailability of adiponectin which is a vasodilator substance released from healthy adipocytes is lost and that this can contribute to an increase in vascular tone and the generation of the conditions that will be predispose to diabetes. We have other projects on-going with regard to the effects of high blood pressure on end-organ damage and the physiological responses to blood pressure in terms of structural reorganisation and its derangement in pathological organisations when blood pressure becomes severe or out of control.

Keywords:

  • Micro-vascular problems (eg nephropathy, retinopathy, neuropathy)
  • Macro-vascular complications of diabetes
 

Methodological Knowledge

  • Action Research
  • Audit/Evaluation
  • Basic Sciences Methods
  • Clinical Trials
 

Teaching

I teach 3rd and 5th year medical students and give lectures to 1st year students.

 

Biography

Tony Heagerty obtained his medical degree in London and his MD in Leicester. He won the International Society of Hypertension Outstanding Young Investigator Award in 1988 and delivered the Royal College of Physicians’ Goulstonian Lecture in 1990. He is Medical Director of the Manchester Wellcome Trust Clinical Research Facility. He is a former President of the European Society of Hypertension and a serving Member of the British Heart Foundation. He is President of the International Society of Hypertension (2008-2010) and in 2009 was elected Vice-President of the British Hypertension Society. He is a Member of the Academic Medicine Committee for the Royal College of Physicians and serves on the Boards of the Journal of Clinical Metabolism & Diabetes, Therapeutic Advances in Cardiovascular Disease, The Open Cardiovascular Medicine Journal, Experimental Physiology, Current Hypertension Reviews, Journal of Hypertension, Hypertension, Diabetes and Vascular Disease Research and Blood Pressure. He is a grant reviewer for Health Boards in New Zealand, France and Holland. In 2006 he received from the European Society of Hypertension the Folkow Award for his studies of the physiology of the circulation in hypertension and in 2007 was Lecturer of the Year and toured Hypertension Centres in Belgium. His clinical interests are in high blood pressure and cardiovascular diseases. He is a Founding Member of the Academy of Medical Sciences. He originally described the concept of structural alterations in the circulation associated with high blood pressure and is currently Head of the Cardiovascular Research Group in Manchester. He is an international authority on high blood pressure, aetiology and management. He holds an Honorary Consultant contract with Manchester Royal Infirmary and holds regular clinics for the treatment of high blood pressure as well as General and Medicine. He is a member of the Institute of Health Sciences Diabetes and Obesity Research Network and is a  Fellow of the High Blood Pressure Council of the American Heart Association.

 

Collaborators and affiliated staff

  • Professor Arthur Weston (Faculty of Life Sciences)
  • Professor Damiano Rizzoni
    University of Brescia, Italy
    Chair of Internal Medicine
  • Professor Enrico Agabati-Rosei
    University of Brescia, Italy
    Professor of Internal Medicine
  • Professor Friedrick Luft
    Universitatsklinikum, Berlin
  • Professor Jan Staeesen
    University Hospital Gathuisberg, Belgium
    Hypertension and Cardiovascular Rehabilitation Unit
 

Publications

2010

  • RH Fagard, G Grassi, J Hall, S Harrap, LH Lindholm, EL Schiffrin and AM Heagerty. (2010). Review of the goals of the committee and of 5 years of ISH activities in low and middle income countries. Journal of Hypertension, 28, 635-636. eScholarID:78088 | DOI:10.1097/01.hjh.0000368700.79444.c1

2009

  • Agabiti-Rosei E, Heagerty AM, Rizzoni D. (2009). Effects of antihypertensive treatment on small artery remodelling. J Hypertens, 27( 6), eScholarID:1d19356 | DOI:10.1097/HJH.0b013e328329272e
  • Greenstein, AS, Kaivan Khavandi, Withers, SB, Sonoyama, KK, olivia clancy, Jeziorska, M, Laing, II, Yates, A, Pemberton, P, Malik, RA, Heagerty, AM. (2009). Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation, 119( 12), eScholarID:1d18910 | DOI:10.1161/CIRCULATIONAHA.108.821181
  • Greenstein, AS, Price, A, Sonoyama, K, Paisley, A, Khavandi, K, Withers, SB, Shaw, LM, Paniagua, O, Malik, RA, Heagerty, AM. (2009). Eutrophic Remodeling of Small Arteries in Type 1 Diabetes Mellitus Is Enabled by Metabolic Control. A 10-Year Follow-Up Study. Hypertension, eScholarID:1d19271 | DOI:10.1161/HYPERTENSIONAHA.109.129718
  • Izzard AS, Emerson M, Prehar SS, Neyses L, Trainer PJ, List EO, Kopchick JJ, Heagerty AM. (2009). The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res, eScholarID:1d19357 | DOI:10.1016/j.ghir.2008.12.006
  • Khavandi K, Khavandi A, Asghar O, Greenstein AS, Withers SB, Heagerty AM, Malik RA. (2009). Diabetic cardiomyopathy--a distinct disease? Best Pract Res Clin Endocrinol Metab, 23( 3), eScholarID:1d19304 | DOI:10.1016/j.beem.2008.10.016
  • Paisley A, Izzard A, Gemmell I, Cruickshank JK, Trainer PJ, Heagerty AM. (2009). Small vessel remodelling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism, 4, 1111-1117. eScholarID:78090

2008

  • Dickens C, McGowan L, Percival CM, Tomenson BM, Cotter LL, Heagerty AM, Creed FH. (2008). Negative illness perceptions are associated with new-onset depression following myocardial infarction. Gen Hosp Psychiatry, 30( 5), eScholarID:1d20398 | DOI:10.1016/j.genhosppsych.2008.04.003
  • Khavandi K, Greenstein AS, Sonoyama KK, Withers SB, Price A, Malik RA, Heagerty AM. (2008). Myogenic tone and small artery remodelling: insight into diabetic nephropathy. Nephrol Dial Transplant, eScholarID:1d18337 | DOI:10.1093/ndt/gfn583
  • Rossi G, Pessina A, Heagerty AM. (2008). Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens, 26( 4), eScholarID:1d19360 | DOI:10.1097/HJH.0b013e3282f4b3e6
  • Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C et al. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 358(15), 1547-1559. eScholarID:133016 | DOI:10.1056/NEJMoa0801317

2006

  • Gönczi M, Szentandrassy NN, Johnson I, Heagerty AM, Weston AA.H. (2006). Investigation of the role of TASK-2 channels in rat pulmonary arteries; pharmacological and functional studies following RNA interference procedures. Br J Pharmacol, 147( 5), 496-505. eScholarID:1d19371 | DOI:10.1038/sj.bjp.0706649
  • Heerkens EH, Shaw LM, Ryding L, Brooker G, Austin CE, Ohanian V, Mullins J, Heagerty AM. (2006). Alpha V integrins are necessary for eutrophic inward remodelling of small arteries in hypertension. Hypertension, 47, 281-287. eScholarID:1d26677 | DOI:10.1161/01.HYP.0000198428.45132.02
  • Kumar, B, Dreja, K, Shah, S, Cheong, A, Xu, S, Sukumar, P, Naylor, J, Forte, A, Cipollaro, M, McHugh, D, Kingston, PA, Heagerty, AM, Munsch, C, Bergdahl, A, Hultgårdh-Nilsson, A, Gomez, M, Porter, K, Hellstrand, P, Beech, D. (2006). Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ Res, 98( 4), eScholarID:1d19370 | DOI:10.1161/01.RES.0000204724.29685.db
  • Lynch FM, Austin CE, Heagerty AM, Izzard AS. (2006). Adenosine and hypoxia-induced dilation of human coronary resistance arteries: evidence against the involvement of KATP channels. British Journal of Pharmacology, 147, 455-458. eScholarID:1d26675 | DOI:10.1038/sj.bjp.0706622
  • Meng, QQ, Lux, A, Holloschi, A, Li, J, Hughes, J, Foerg, T, McCarthy, J, Heagerty, AM, Kioschis, P, Hafner, M, Garland, JM. (2006). Identification of Tctex2beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors. J Biol Chem, 281( 48), 37069-80. eScholarID:1d19368 | DOI:10.1074/jbc.M608614200
  • Wilkinson FL, Liu Y, Rucka A, Jeziorska M, Hoyland JA, Heagerty AM, Canfield AE, Alexander MY. (2006). Contribution of VCAF-positive cells to neovascularization and calcification in atherosclerotic plaque development. J Pathol, 211(3), 362-369. eScholarID:1d14848

2005

  • Alexander MY, Wilkinson FL, Kirton J, Rock C, Collett GGDM, Jeziorska M, Smyth J, Heagerty AM, Canfield AE. (2005). Identification and characterization of vascular calcification-associated factor, a novel gene upregulated during vascular calcification in vitro and in vivo. Arterioscler Thromb Vasc Biol, 25(9), eScholarID:1d12061
  • Malik RA, Schofield I, Izzard AS, Austin CE, Bermann G, Heagerty AM. (2005). Effects of angiotensin Type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus. Hypertension, 45, 264-269.. eScholarID:1d26111 | DOI:10.1161/01.HYP.0000153305.50128.a1

2004

  • Gardener M, Johnson I, Burnham MMP, Edwards G, Heagerty AM, Weston AA.H. (2004). Functional evidence of a role for two-pore domain potassium channels in rat mesenteric and pulmonary arteries. Br J Pharmacol, 142( 1), 192-202. eScholarID:1d19378 | DOI:10.1038/sj.bjp.0705691
  • Super M, Irtiza-Ali A, Roberts SA, Schwarz M, Young M, Smith A, Roberts T, Hinks J, Heagerty AM. (2004). Blood pressure and cystic fibrosis gene: evidence for lower pressure rises with age in female carriers. Hypertension, 44(6), 878-883. eScholarID:1d8727 | DOI:10.1161/01.HYP.0000145901.81989.46

2003

  • Appleby C, Kingston PA, David A, Gerdes G A, Umana P, Castro M G, Lowenstein P R, Heagerty AM. (2003). A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer. Gene Therapy, 10, 1616-1622. eScholarID:1d7275 | DOI:10.1038/sj.gt.3302044

2002

  • Canfield AE, Farrington Clare, Dziobon M, Boot-Handford RR, Heagerty AM, Kumar Shant, Roberts Ian S. (2002). The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol, 196( 2), 228-34. eScholarID:1d19382 | DOI:10.1002/path.1020
  • Schofield I, Malik RA, Izzard AS, Austin CE, Heagerty AM. (2002). Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the role of abnormal myogenic responsiveness and dyslipidemia. Circulation, 106, 3037-3043. eScholarID:1d2346 | DOI:10.1161/01.CIR.0000041432.80615.A5
  • Sinha SS, Heagerty AM, Shuttleworth CC.A, Kielty CM. (2002). Expression of latent TGF-beta binding proteins and association with TGF-beta 1 and fibrillin-1 following arterial injury. Cardiovasc Res, 53( 4), 971-83. eScholarID:1d19380

2001

  • Sinha SS, Kielty CM, Heagerty AM, Canfield AE, Shuttleworth CC.A. (2001). Upregulation of collagen VIII following porcine coronary artery angioplasty is related to smooth muscle cell migration not angiogenesis. Int J Exp Pathol, 82( 5), 295-302. eScholarID:1d19384

2000

  • Garland JM, Kumar S, Heagerty AM. (2000). Angiogenesis in CML. Lancet, 356, 1026-1027. eScholarID:17d80

1998

  • Farrington CC, Roberts I, Heagerty AM, Canfield AE. (1998). The expression of cartilage oligomeric matrix protein, thrombospondin-1, bone sialoprotein and osteopontin in calcified and non-calcified arterial lesions. Biochem Soc Trans, 26( 1), eScholarID:1d19389

1997

  • ISD Roberts, Farrington CC, DJA Goldsmith, HS Neild, McCollum CN, Heagerty AM, Canfield AE. (1997). The expression of osteopontin and thrombospondin-1 in calcified and non-calcified arterial lesions. Journal Of Pathology, 181, A31. eScholarID:17d99
  • M Kale, Boot-Handford RP, Heagerty AM, Canfield Ann. (1997). Characterisation of genes expressed during the early stages of VEGF-induced angiogenesis. International Journal Of Experimental Pathology, 78, eScholarID:17d100

1996

  • Ohanian V, Ohanian J, Shaw LM, Scarth S, Parker P, Heagerty AM. (1996). Identification of protein kinase C isoforms in rat mesenteric small arteries and their possible role in agonist-induced contraction. Circ Res, 78( 5), eScholarID:1d20568

Top of page

| Skip to main content | Skip to navigation | Skip to Search |